Catalog No.: PC-25354Not For Human Use, Lab Use Only.
LPM4870108 is a next-generation, potent pan-Trk inhibitor with IC50 of 0.2 nM, 2.4 nM, 3.5 nM and 2.3 nM for TrkC, TrkA, TrkAG595R and TrkAG667C, respectively, shows high selectivity over ALK (IC50=182 nM).
LPM4870108 is a next-generation, potent pan-Trk inhibitor with IC50 of 0.2 nM, 2.4 nM, 3.5 nM and 2.3 nM for TrkC, TrkA, TrkAG595R and TrkAG667C, respectively, shows high selectivity over ALK (IC50=182 nM).
LPM4870108 (5, 10, or 20 mg/kg) produced significant inhibition of tumor growth both in wild-type NTRK fusion mutation cells (Ba/F3 LMNA-NTRK1cells and Ba/F3 ETV6-NTRK3 cells) and drug-resistant mutation cells (Ba/F3 ETV6-NTRK3-G623R cells and Ba/F3 LMNA-NTRK1-G595R).
LPM4870108 is more efficacious and safer against tumor growth than LOXO-195.
